Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
No-observed-adverse-effect-level (NOAEL) was considered to be 1000 mg/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reason / purpose for cross-reference:
- read-across source
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test item-related changes of toxicological relevance were noted during daily observations in rats at any dose level.
Orange feces were recorded in males and females treated with 1000 mg/kg bw/day from day 2 of treatment onwards, and persisted for two days of the recovery period. This was considered to be a typical passive effect resulting from large oral doses of a dyestuff.
Diverse alopecia was noted in one control male (days 12-16), one control female (days 27-29), and one female treated with 1000 mg/kg bw/day (days 20-28), accompanied in the latter case with a dermal scab (days 20-25). The low incidence of dermal findings in test item treated rats was considered to be incidental.
DETAILED CLINICAL OBSERVATIONS (WEEKLY)
No test item-related changes of toxicological relevance were noted during weekly observations (weeks 1-3) in rats at any dose level. Diverse alopecia was recorded in one control male at week 2 and in one high dose female (accompanied by a dermal scab) at week 3. - Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One control male (no. 8) was found dead shortly after administration on day 22. Dosing error was considered to be a possible cause of death. All other animals survived until scheduled necropsy.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- The mean body weights and the body weight gain of the control and test item-treated rats were similar.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The mean daily food consumption of the test item-treated rats compared favorably with those of the controls during the treatment and recovery periods.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No test item-related differences in the hematology parameters were noted in any dose level after the treatment and recovery periods.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test item-related differences in the clinical biochemistry parameters were noted in any dose level after the treatment or recovery periods.
Significant reductions of the mean calcium levels in males treated with 50 mg/kg bw/day (p<0.01) and 1000 mg/kg/day (p<0.05), and significant elevations of the mean sodium level in males treated with 1000 mg/kg bw/day (p<0.05) and chloride level in males treated with 50 mg/kg bw/day (p<0.05) were considered to be incidental in the absence of other changes in electrolytes.
After the recovery period in males previously treated with 1000 mg/kg bw/day significantly reduced mean plasma concentrations were noted in creatinine (p<0.05), alanine aminotransferase (p<0.01) and globulin (p<0.01). In females previously treated with 1000 mg/kg bw/day significantly elevated mean plasma concentrations were noted in total bilirubin (p<0.05), triglycerides (p<0.01), calcium (p<0.05), protein (p<0.05) and albumin (p<0.05). These changes were not considered to be late effects of toxicological relevance. - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test item-related differences in the urinalysis parameters were noted in any dose level after the treatment or recovery periods.
In males treated with 1000 mg/kg/day leukocyte concentration was significantly elevated (p<0.05) and urine appearance was cloudy to turbid. In females treated with 1000 mg/kg bw/day nitrite was found in the urine. Both findings were considered to be unrelated to the test item and may result from spontaneous bacterial activity in urinary tract. - Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test item-related changes of toxicological relevance were noted during functional observational battery (week 4) in rats at any dose level. Diverse alopecia was recorded in one high dose female at week 4.
Grip Strength
The mean fore- and hind limb grip strength of the test item-treated rats were similar to those of the controls.
Locomotor Activity
In females treated with 1000 mg/kg bw/day, elevated mean locomotor activity was noted from 0-10 minutes (p<0.01), 10-20 minutes (p<0.01) and 20-30 minutes (p<0.05). These differences resulted in an overall increase (p<0.01, 0-60 minutes) when compared with controls. As similar differences were not seen in males, a relationship with the test item treatment was considered unlikely. All differences noted in females treated with 50 mg/kg bw/day or 200 mg/kg bw/day were considered to be of no toxicological relevance.
In test item-treated males, the mean locomotor activity was not affected by the test item administration. The slightly elevated locomotor activities recorded from 30-40 minutes (p<0.05) in males treated with 50 mg/kg bw/day resulted in significant changes in the overall locomotor activity (p<0.05, 0-60 minutes), as well as from 0-10 minutes (p<0.05) and 30-40 minutes (p<0.05) of males treated with 200 mg/kg/day. In the absence of any dose-response relationship, these changes were considered to be incidental. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- After 4 Weeks
The mean absolute and relative organ weights of the test item-treated rats and the control rats were similar.
After 6 Weeks
No test item-related changes were noted in the mean absolute and relative organ weights of rats previously treated with 1000 mg/kg bw/day. In males previously treated with 1000 mg/kg bw/day, the mean absolute liver weights were reduced (p<0.01) when compared with controls, and the mean brain-to-body weight ratio was increased (p<0.01) when compared with controls. The elevated mean absolute brain weight resulted in reduced organ-to-brain weight ratios for heart (p<0.05), liver (p<0.01), kidneys (p<0.01) and adrenals (p<0.05). These differences were considered to be artifacts and of no toxicological relevance. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- After the treatment and recovery periods no test item-related gross lesions were observed. The macroscopic findings recorded were considered to be within the range of normal background lesions, which may seen in rats of this strain and age in this study type and were considered incidental, reflecting the usual individual variability.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- A variety of changes were found in this study. These findings commonly occur in laboratory rats of this strain and age, neither their incidences nor their distribution or morphologic characteristics gave any indication of a treatment-related association.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Critical effects observed:
- no
- Conclusions:
- The no-observed-adverse-effect-level (NOAEL) was considered to be 1000 mg/kg bw/day.
- Executive summary:
No study is available for assessment of toxicity on repeated exposure to FAT 41048. However, structural analogue, FAT 41039/A was evaluated for potential to cause toxicity on repeated exposure in a study conducted according to OECD Guideline 407 and EU Method B.7. Oral administration of FAT 41039/A to Wistar rats at doses of 50, 200 and 1000 mg/kg bw/day, for 28 days resulted in no test item-related deaths (one control male died from a suspected dosing error), no clinical signs during daily or weekly (weeks 1-3) observations, no clinical signs during the functional observation battery (week 4), no effects upon fore- or hindlimb grip strength or mean locomotor activity, mean daily food consumption and mean body weight, no changes or effects upon hematology, clinical biochemistry or urinalysis and no changes in mean absolute or relative organ weights. No macroscopical or microscopical changes of toxicological relevance were seen at any dose level. Therefore, the no-observed-adverse-effect-level (NOAEL) was considered to be higher than the highest dose level tested, 1000 mg/kg bw/day. Using the principles of read across, NOAEL for FAT 41048 when orally administered over 28 days was considered to be 1000 mg/kg bw/day.
Reference
None
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Good quality GLP study
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Mode of Action Analysis / Human Relevance Framework
None
Additional information
No study is available for assessment of toxicity on repeated exposure to FAT 41048. However, structural analogue, FAT 41039/A was evaluated for potential to cause toxicity on repeated exposure in a study conducted according to OECD Guideline 407 and EU Method B.7. Oral administration of FAT 41039/A to Wistar rats at doses of 50, 200 and 1000 mg/kg bw/day, for 28 days resulted in no test item-related deaths (one control male died from a suspected dosing error), no clinical signs during daily or weekly (weeks 1-3) observations, no clinical signs during the functional observation battery (week 4), no effects upon fore- or hindlimb grip strength or mean locomotor activity, mean daily food consumption and mean body weight, no changes or effects upon hematology, clinical biochemistry or urinalysis and no changes in mean absolute or relative organ weights. No macroscopical or microscopical changes of toxicological relevance were seen at any dose level. Therefore, the no-observed-adverse-effect-level (NOAEL) was considered to be higher than the highest dose level tested, 1000 mg/kg bw/day. Using the principles of read across, NOAEL for FAT 41048 when orally administered over 28 days was considered to be 1000 mg/kg bw/day.
Justification for classification or non-classification
FAT 41048 is considered to have no adverse effects on repeated exposure upto 1000 mg/kg bw/day. Hence, the substance does not warrant classification as per the Regulation (EC) No. 1272/2008 (CLP) criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.